Skip to Main Content

Evaluating the Safety, Tolerability, Pharmacokinetics and Receptor Occupancy of BMS-984923

Conditions

Men's Health | Women's Health

What is the purpose of this trial?

This project seeks to develop a novel disease-modifying compound for Alzheimer's disease (AD).

  • Trial with
    Alzheimer's Association
  • Start Date
    03/25/2021
  • End Date
    06/01/2022

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    06/26/2022
  • Study HIC
    #2000028864